Literature DB >> 12873176

Accurate Gleason grading of prostatic adenocarcinoma in prostate needle biopsies by general pathologists.

Andrew A Renshaw1, Delray Schultz, Kerri Cote, Marian Loffredo, David E Ziemba, Anthony V D'Amico.   

Abstract

CONTEXT: Gleason grading of prostatic adenocarcinoma in core needle biopsies is important for predicting prognosis and selecting appropriate therapy. Previous studies have shown that Gleason scores assigned by general pathologists have a low correlation with those assigned by urologic pathologists, and that general pathologists tend to undergrade prostate carcinoma.
OBJECTIVE: To determine if the performance of general pathologists grading prostate needle biopsies has changed over time.
DESIGN: Four hundred sixteen prostate biopsies from men treated at a single community-based institution between 1987 and 2000 were reviewed by one urologic pathologist (A.A.R.). The correlation between the original Gleason score and the reviewer's score was determined over time.
RESULTS: Cases were divided into those performed and originally interpreted in the first half of the study (1987-1996) and those performed and originally interpreted in the second half (1996-2000). Overall concordance for exact Gleason score was 59% (244/416). The exact concordance of the Gleason score assigned by the original pathologist and the reviewer during the first half of the study was 51%, whereas in the second half of the study the concordance was significantly greater (66.3%, P =.002). However, when grouped into score categories of 6 or less, 7, and 8 or greater, there was no significant difference in the exact concordance between the first half of the study (78.3%) and the second half (78.4%). Fifty-five percent of the cases in which there was discordance were graded as 7 by the reference pathologist and 6 or less by the original pathologist. There was no correlation between concordance in Gleason score and the percentage of tissue involved by carcinoma.
CONCLUSION: The concordance between general pathologists' Gleason grading and that of a reference pathologist in this study is much higher than that in previously reported studies. Although exact concordance has significantly improved over time, concordance by clinically significant groups has remained high throughout the study, is dominated by the difference between Gleason score 7 and 6 or less, and is unrelated to the size of the tumor focus.

Entities:  

Mesh:

Year:  2003        PMID: 12873176     DOI: 10.5858/2003-127-1007-AGGOPA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  12 in total

Review 1.  The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer.

Authors:  Matthew S Katz; Jason A Efstathiou; Anthony V D'Amico; Michael W Kattan; Martin G Sanda; Paul L Nguyen; Matthew R Smith; Peter R Carroll; Anthony L Zietman
Journal:  BJU Int       Date:  2010-03-15       Impact factor: 5.588

2.  The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer.

Authors:  Al B Barqawi; Ruslan Turcanu; Eduard J Gamito; Scott M Lucia; Colin I O'Donnell; E David Crawford; David D La Rosa; Francisco G La Rosa
Journal:  Int J Clin Exp Pathol       Date:  2011-06-12

3.  Temporal changes in the pathologic assessment of prostate cancer.

Authors:  M Scott Lucia; Adrie van Bokhoven
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

4.  Frequency and determinants of disagreement and error in gleason scores: a population-based study of prostate cancer.

Authors:  Michael Goodman; Kevin C Ward; Adeboye O Osunkoya; Milton W Datta; Daniel Luthringer; Andrew N Young; Katerina Marks; Vaunita Cohen; Jan C Kennedy; Michael J Haber; Mahul B Amin
Journal:  Prostate       Date:  2012-01-06       Impact factor: 4.104

5.  Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial).

Authors:  Mei Lu; Svend O Freytag; Hans Stricker; Jae Ho Kim; Kenneth Barton; Benjamin Movsas
Journal:  Contemp Clin Trials       Date:  2011-02-12       Impact factor: 2.226

6.  Prostate gland biopsies and prostatectomies: an Ontario community hospital experience.

Authors:  Ken J Newell; John F Amrhein; Rashmikant J Desai; Paul F Middlebrook; Todd M Webster; Barry W Sawka; Brian F Rudrick
Journal:  Can Urol Assoc J       Date:  2008-10       Impact factor: 1.862

7.  Factors predicting pathological upgrading after prostatectomy in patients with Gleason grade group 1 prostate cancer based on opinion-matched biopsy specimens.

Authors:  Yuki Maruyama; Takuya Sadahira; Motoo Araki; Yosuke Mitsui; Koichiro Wada; Acosta Gonzalez Herik Rodrigo; Kazuaki Munetomo; Yasuyuki Kobayashi; Masami Watanabe; Hiroyuki Yanai; Toyohiko Watanabe; Yasutomo Nasu
Journal:  Mol Clin Oncol       Date:  2020-02-10

8.  Establishment of a new prostate cancer multidisciplinary clinic: Format and initial experience.

Authors:  Debasish Sundi; Jason E Cohen; Alexander P Cole; Brian P Neuman; John Cooper; Farzana A Faisal; Ashley E Ross; Edward M Schaeffer
Journal:  Prostate       Date:  2014-10-13       Impact factor: 4.104

9.  Yet Another Automated Gleason Grading System (YAAGGS) by weakly supervised deep learning.

Authors:  Yechan Mun; Inyoung Paik; Su-Jin Shin; Tae-Yeong Kwak; Hyeyoon Chang
Journal:  NPJ Digit Med       Date:  2021-06-14

10.  A second opinion pathology review improves the diagnostic concordance between prostate cancer biopsy and radical prostatectomy specimens.

Authors:  Takanori Maehara; Takuya Sadahira; Yuki Maruyama; Koichiro Wada; Motoo Araki; Masami Watanabe; Toyohiko Watanabe; Hiroyuki Yanai; Yasutomo Nasu
Journal:  Urol Ann       Date:  2021-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.